The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Innate Pharma S.A. (Innate or the Company) (NASDAQ: IPHA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Innate announced on January 9, 2020, that it would suspend enrollment of new patients in the TELLOMAK Phase II trial of lacutamab (IPH4102). The trial was designed to evaluate the efficacy and safety of lacutamab in patients with advanced T-cell lymphomas. The Companys decision was based on ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Companys manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials. Based on this news, shares of Innate fell by nearly 10% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.